Healthcare / Medical Instruments & SuppliesNasdaqCM
$26.63
+1.71 (+6.86%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $416000.00 · quality 46.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
38/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.3B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-1.2%
↓Gross Margin
64.6%
↑Debt/Equity
0.05
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2010–2025 · 15 años de histórico normalizado
Revenue CAGR
+29.1%
FCF CAGR
—
FCF margin
0.4%
FCF / Net income
-0.09x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $96.2M · net income $-4.6M · FCF $416000.0
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||||
| Revenue | $96.2M | $96.2M | $74.6M | $68.0M | $76.2M | — | — | — | — | — | — | — | $6.2M | $8.9M | $5.7M | $2.8M | $2.1M |
| Net Income | $-4.6M | $-4.6M | $-20.2M | $-68.0M | $-139.8M | $-8.9M | $2.0M | $-1.7M | $-25.0M | $-2.5M | $-6.9M | $-4.2M | $-3.2M | $-1.1M | $-1.7M | $-2.0M | $-2.0M |
| EBITDA | $-11.9M | $-11.9M | $4.2M | $-7.1M | $5.8M | $-30.5M | $-4.2M | $498000.00 | — | — | — | — | — | — | — | — | — |
| EPS | -0.10 | -0.10 | -0.44 | -1.55 | -3.29 | -0.23 | -0.06 | -0.09 | -1.56 | -0.21 | — | — | — | — | — | — | — |
| Gross Margin | 64.6% | 64.6% | 67.1% | 60.7% | 61.5% | — | — | — | — | — | — | — | 49.0% | 42.0% | 40.5% | 50.9% | 41.1% |
| Operating Margin | -17.3% | -17.3% | -6.0% | -28.5% | -14.0% | — | — | — | — | — | — | — | -50.7% | -3.2% | -16.6% | -43.8% | -67.0% |
| Net Margin | -4.8% | -4.8% | -27.0% | -100.0% | -183.4% | — | — | — | — | — | — | — | -52.0% | -12.1% | -29.3% | -70.9% | -95.3% |
| Balance Sheet | |||||||||||||||||
| Debt/Equity | 0.05 | 0.05 | 0.09 | 0.10 | 0.12 | 0.01 | 0.00 | 0.00 | — | — | 1.34 | — | — | — | — | — | — |
| Current Ratio | 7.30 | 7.30 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||||||
| Free Cash Flow | $416000.00 | $416000.00 | $4.9M | $-18.9M | $-18.9M | $-13.0M | $4.7M | $538000.00 | $1.8M | $461000.00 | $-4.5M | $-5.1M | $-3.8M | $-90663.00 | $-296786.00 | $-1.1M | $-1.3M |
| Returns | |||||||||||||||||
| ROE | -1.2% | -1.2% | -5.8% | -20.1% | -38.4% | -1.9% | 1.0% | -3.8% | -170.9% | 26.4% | -217.1% | -49.5% | -23.1% | 8.2% | 13.3% | 17.5% | 20.8% |
| Valuation | |||||||||||||||||
| EV/EBITDA | — | — | 276.19 | — | 140.24 | — | — | — | — | — | — | — | — | — | — | — | — |
| P/B | 3.48 | 3.48 | 3.49 | 2.03 | 2.16 | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||||||
| Revenue Growth | 28.9% | 28.9% | 9.7% | -10.8% | — | — | — | — | — | — | — | — | -30.8% | 58.0% | 105.3% | 32.5% | — |
| EPS Growth | 77.3% | 77.3% | 71.6% | 52.9% | — | -283.3% | 33.3% | 94.2% | -642.9% | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+21.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.44 → -0.10
Residual
+21.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.